Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis.
Benheng QianKexin LiXiaoying LouYe GuoYidong WangLianpin WuDonghong ZhangPublished in: Cells (2022)
Atherosclerosis (AS) is the leading cause of cardiovascular diseases (CVDs) with a high rate of mortality worldwide. Plasma cell-free DNA (cfDNA), mainly originating from apoptosis, necrosis, and active secretion, has been recognized as a promising biomarker for the diagnosis and prognosis of multiple cancers, whereas there are no reports about cfDNA in CVDs. Here, we found an increased quantity and decreased integrity of cfDNA (cfDI) in the serum from AS patients compared with normal controls. Moreover, the reduced cfDI is inversely correlated with serum LDL levels, carotid plaque size, and carotid plaque thickness in the progression of AS. Consistently, in vivo experiments confirmed that the release and cleavage of cfDNA were increased concomitantly with the development and progression of AS in ApoE - / - mice. Our study sheds light on the potential of cfDNA and cfDI as molecular biomarkers for detecting and monitoring AS.
Keyphrases
- cardiovascular disease
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- oxidative stress
- cardiovascular events
- peritoneal dialysis
- type diabetes
- cell death
- risk factors
- high fat diet
- emergency department
- dna binding
- patient reported outcomes
- cell proliferation
- signaling pathway
- cardiovascular risk factors